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1p21-22 in bladder cancer
Mauro Scaravilli1, Paola Asero1, Teuvo LJ Tammela1,2, Tapio Visakorpi1 and Outi R Saramäki1*Abstract
Background: The aim of the study was to characterize a recurrent amplification at chromosomal region 1p21-22 in
bladder cancer.
Methods: ArrayCGH (aCGH) was performed to identify DNA copy number variations in 7 clinical samples and 6
bladder cancer cell lines. FISH was used to map the amplicon at 1p21-22 in the cell lines. Gene expression microarrays
and qRT-PCR were used to study the expression of putative target genes in the region.
Results: aCGH identified an amplification at 1p21-22 in 10/13 (77%) samples. The minimal region of the amplification
was mapped to a region of about 1 Mb in size, containing a total of 11 known genes. The highest amplification was
found in SCaBER squamous cell carcinoma cell line. Four genes, TMED5, DR1, RPL5 and EVI5, showed significant
overexpression in the SCaBER cell line compared to all the other samples tested. Oncomine database analysis revealed
upregulation of DR1 in superficial and infiltrating bladder cancer samples, compared to normal bladder.
Conclusions: In conclusions, we have identified and mapped chromosomal amplification at 1p21-22 in bladder cancer
as well as studied the expression of the genes in the region. DR1 was found to be significantly overexpressed in the
SCaBER, which is a model of squamous cell carcinoma. However, the overexpression was found also in a published
clinical sample cohort of superficial and infiltrating bladder cancers. Further studies with more clinical material are
needed to investigate the role of the amplification at 1p21-22.
Keywords: Gene amplification, Bladder cancer, DR1, aCGHBackground
Bladder cancer is the fourth most common cancer in men
in developed countries and the second most common ma-
lignancy of the urinary tract [1]. The majority of bladder
cancer cases arise from the urothelium, the epithelium
lining the inside of the bladder and these cases are thus
called urothelial carcinomas. Squamous cell carcinoma of
the urinary bladder is a rarer malignant neoplasm and it
accounts for 3–5% of bladder cancer in Western popula-
tions [2].
Several studies have investigated the chromosomal alter-
ations associated with development and progression of
bladder cancer. Different methods to detect copy number
changes, such as classical cytogenetics, interphase fluores-
cence in situ hybridization (FISH), Southern blot analysis,* Correspondence: outi.saramaki@uta.fi
1Prostate Cancer Research Center, Institute of Biosciences and Medical
Technology - BioMediTech, University of Tampere and Tampere University
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unless otherwise stated.quantitative polymerase chain reaction (PCR)-based assays
and comparative genomic hybridization (CGH) have been
used [3].
Several CGH studies providing information about typ-
ical losses, gains and amplifications in bladder cancer have
been published [4-8]. However, the resolution of conven-
tional CGH is generally limited to regions greater than
10 Mb. The development of array-based technologies for
CGH [9,10] led to > 10-fold increase of the resolution and
consequently to the analysis of copy number alterations at
single gene level. A few array-CGH (aCGH) genome-wide
studies have been performed on both clinical bladder
cancers [11,12] as well as cell lines [13]. They have
highlighted copy-number alterations in smaller scale, with
high accuracy of localization. Some of these genetic
changes have been associated with known oncogenes or
tumor suppressor genes. Loss of genetic material on
chromosome 9 is one of the most frequent alteration in
TCC, with 9p and 9q, often both, lost entirely or in partl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 FISH mapping of 1p21-22 amplicon
Clones Chromosome location Cell lines
SCaBER HT-1376 UM-UC-3 TCCSUP RT4 J82 T24 5637
RP11-82E1 91,116,728–91,294,152 3/4 (0.9) 3/3 (1.00)
RP5-865 M20 92,068,692–92,181,253 2/4 (0.54) 10/6 (1,53) 3/4 (0.86) 4/4 (0.98) 3/3 (1.00) 3/3 (1.17) 3/3 (1.00)
RP4-621B10 92,517,154–92,659,879 2/4 (0.54) 10/6 (1.89) 3/4 (0.86) 4/4 (1.00) 3/3 (1.00) 3/3 (1.12) 3/3 (1.00)
RP5-1014C4 92,854,755–93,007,879 7/4 (2.02) 11/6 (1.91) 4/4 (1.02) 3/3 (1.00)
RP11-977E2 93,042,494–93,249,510 8/4 (2.35) 10/6 (1.65) 3/4 (0.75) 3/4 (0.73) 4/4 (0.93) 3/3 (0.86) 4/3 (1.24) 3/3 (1.00)
RP5-976O13 93,529,940–93,632,330 10/4 (3.07) 10/6 (1.64) 3/4 (0.78) 3/3 (1.06) 3/3 (1.00)
RP4-713B5 93,760,493–93,865,044 11/4 (3.02) 10/6 (1.83) 3/3 (1.00)
RP11-272P3 94,980,681–95,180,686 3/4 (0.99) 11/6 (1.91) 3/3 (1.00)
RP11-146P11 95,983,612–96,156,674 4/4 (1.04) 10/6 (1.85) 4/4 (1.05) 3/4 (0.82) 4/4 (1.05) 3/3 (0.93) 3/3 (1.00)
RP11-122C9 97,095,507–97,282,884 3/4 (1.07) 10/6 (1.91) 3/3 (1.00)
The first value represents the median of signals from the locus-specific probe indicated under ‘clones’; the second value represents the median number of signal
from the chromosome 1 centromeric probe. The ratio between the two values is bracketed. SCaBER cell line shows a high level amplification between the
positions 92,854,755 and 93,865,044 (GRCh37/h19), whereas HT-1376 cell line shows a copy-number gain.
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DBCCR1 [17], and TSC1 [18]. Deletion of 10q has been
associated with PTEN locus [19,20], 13q with RB1 [21]
and 17p with TP53 [22]. Common DNA amplifications
contain known or candidate oncogenes as well, including
cyclin D1 (CCND1) at 11q13 [23,24], ERBB2 at 17q21
[25,26], E2F3 at 6p22 [27,28], MDM2 at 12q14 [29], and
MYC at 8q24 [30]. Recurrent amplifications have also
been found at 1q, 3p, 3q, 8p, 8q, and 12q [5,6,8]. Further-
more, activating mutations of oncogenes HRAS [31] and
FGFR3 [32] seem to be common. Gain-of-function muta-
tions affecting RAS and FGFR3 and loss-of-function muta-
tion affecting RB, PTEN and TP53 have also been
associated with the pathological stage and/or outcome of
bladder cancer [33,34].
In this study, we report the characterization of a com-
mon amplification at chromosomal region 1p21-22. The
amplicon was identified by aCGH analysis of clinical
specimens obtained from bladder cancer patients and in
bladder cancer cell lines.
Methods
Clinical samples
Freshly frozen samples from 7 bladder cancer tissues
were used for this study. The samples were obtained
from Tampere University Hospital and include five
urothelial carcinomas, one lymphoepithelial carcinomaTable 2 PCR primers
Gene Forward primer
DR1 TGCAAGAGTGTAAAAAGTAGCATT
EVI5 AGCAGAGTGATGAGGCCAGT
RPL5 TGGAAGAAGATGAAGATGCTTAC
TMED5 TCACACCTTCCCTCGATAGC
TBP GAATATAATCCCAAGCGGTTTGand one undifferentiated carcinoma. DNA was extracted
using DNAzol reagent (Molecular Research Center, Inc.
Cincinnati, OH), according to manufacturer’s protocol.
The use of the clinical samples was approved by the eth-
ical committee of the Tampere University Hospital.
Cell lines
The bladder cancer cell lines UM-UC-3, TCCSUP, RT4,
T24, HT-1376, J82, SCaBER, 5637, HT-1197 and SW780
were obtained from the American Type Culture Collec-
tion (ATCC, Rockville, MD, USA) and cultured according
to the recommended conditions.
Array comparative genomic hybridization
16 K cDNA microarray-slides were obtained from
the Finnish Microarray DNA Centre (http://www.btk.fi/
microarray-and-sequencing/) (Turku Centre for Biotech-
nology, University of Turku and Åbo Akademi University,
Turku, Finland). The poly-L-lysine coated slides contain ap-
proximately 16000 annotated clones from sequence verified
I.M.A.G.E. Consortium cDNA library in duplicate. Com-
parative genomic hybridization to microarray (aCGH) was
done as described previously [35]. Briefly, 2 to 10 μg RsaI-
digested (Fermentas UAB, Vilnius, Lithuania) DNA was
labeled with Cy5-dCTP, and normal male reference DNA
with Cy3-dCTP (Amersham Biosciences UK Ltd., Little
Chalfont, United Kingdom), using a BioPrime Labeling KitReverse primer
TGCTGCATTTGAAGCCATT
CTTCACTCAGTCGGGCTTG
GACGACATACCTCTTCTTTTTAACTTC
AAGGTTTTGCCTTCTGGAGAG
ACTTCACATCACAGCTCCCC
Figure 1 Fluorescence in situ hybridization. (a) HT-1376 cell line nuclei hybridized with the BAC clone RP11-122C9 showing copy number gain
(RED: RP11-122C9, GREEN: pericentromeric chr.1), and (b) nuclei of SCaBER squamous cell carcinoma cell line model hybridized with the PAC
clone RP4-713B5, showing a high level amplification (colors as in a).
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hybridized overnight at +65°C, under cover slips, to micro-
array slides, in a final volume of 38.5 μl of hybridization
mix containing 3.4 × SSC, 0.3% SDS, 1.3 ×Denhardt’s
(Sigma-Aldrich, St. Louis, MO), and 0.5 ×DIG Blocking
Buffer (Roche Diagnostics, Mannheim, Germany). After
stringent washes, the slides were scanned with ScanAr-
ray4000 confocal laser scanner (Perkin Elmer, Boston, MA).
Signal volumes were quantified using the QuantArray soft-
ware program (Packard Bioscience, Bio- Chip Technology
LCC, Billerica, MA). Data were analyzed using the cluster
along chromosomes (CLAC) algorithm, as previously de-
scribed and visualized using the software CGH-Miner [36].
Fluorescence in situ hybridization
Human genome PAC/BAC clones were purchased from
Invitrogen™ Corporation. The list of clones is shown in
Table 1 and the chromosome positions are indicated
according to UCSC (University of California Santa Cruz)
Genome Browser, February 2009 assembly (GRCh37/h19).
The clones were labeled with digoxigenin-dUTP (Roche
Diagnostics) or Alexa Fluor®-dUTP (Invitrogen™) by nickTable 3 Known human genes at chromosome 1 position 92,9
NAME DESCRIPTION
GFI1 Growth factor independent 1 transcription repressor (GFI1
EVI5 Ecotropic viral integration site 5 (EVI5)
RPL5 Ribosomal protein L5 (RPL5)
SNORD21 Small nucleolar RNA, C/D box 21 (SNORD21), small nucleo
SNORA66 Small nucleolar RNA, H/ACA box 66 (SNORA66), small nuc
FAM69A Family with sequence similarity 69, member A (FAM69A)
MTF2 Metal response element binding transcription factor 2 (MT
TMED5 Transmembrane emp24 protein transport domain contain
CCDC18 Coiled-coil domain containing 18 (CCDC18)
LOC100131564 Uncharacterized LOC100131564 (LOC100131564), non-cod
DR1 Down-regulator of transcription 1, TBP-binding (negative ctranslation. A pericentromeric probe for chromosome 1
labeled with FITC-dUTP was obtained from Roche. The
metaphase slides from the bladder cancer cell lines were
prepared using standard techniques. The slides were dena-
tured in 70% formamide/2xSSC at 70°C for 2 min and
dehydrated in an ascending ethanol series. Hybridization
was performed over night at 37°C. After stringent washes,
the slides were stained with antidigoxigenin-rhodamine
(Roche Diagnostics) for the digoxigenin-labeled probes
and embedded in an antifade solution (Vectashied, Vector
Laboratories, Burlingame, CA, USA) containing 4,6-dia-
midino-2-phenylindole (DAPI) as counter stain. Stained
slides were analyzed on an epifluorescence microscope
(Olympus) and acquired images were processed using
Image-Pro® image-processing software (Media Cybernet-
ics). A total of 50 nuclei were considered for statistical
analysis of the FISH signals in each experiment. An ampli-
fication was defined as a locus-specific probe/centromere
ratio >2. In each experiment the hybridization efficiency
of the locus-specific and centromeric probes was evalu-
ated using 5637 bladder cancer cell line as a triploid
control.40,318 - 93,828,148 (GRCh37/h19)
LOCATION GENOMIC SIZE (bp)
) chr1:92,940,318 – 92,952,433 12116
chr1:92,974,253 – 93,257,961 283709
chr1:93,297,594 – 93,307,481 9887
lar RNA chr1:93,302,846 – 93,302,940 95
leolar RNA chr1:93,306,276 – 93,306,408 133
chr1:93,307,717 – 93,427,079 128794
F2) chr1:93,544,792 – 93,604,638 59847
ing 5 (TMED5) chr1:93,615,299 – 93,646,246 30948
chr1:93,646,281 – 93,744,287 98007
ing RNA chr1:93,775,666 – 93,811,368 35703
ofactor 2) (DR1) chr1:93,811,478 – 93,828,148 16671
Figure 2 (See legend on next page.)
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Figure 2 Fine mapping the region of amplification. Chromosome 1 ideogram showing the region of amplification according to aCGH
(above), the FISH scoring data on SCaBER cell lines indicating the minimal region of amplicon (in gray), and (below) an expression heatmap of
the genes at chromosome 1, position 92,940,318 – 93,828,148 (red: overexpression, blue: underexpression), showing significant relative
overexpression of TMED5, DR1, EVI5 and RPL5 in the SCaBER cell line.
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Total RNA from bladder cancer cell lines was collected
and extracted using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA), according to the manufacturer’s protocol. The
samples were then amplified and hybridized using the
Agilent whole genome oligo microarray platform (Agilent
Technologies, Palo Alto, CA, USA) and Xpress Ref ™
Human Universal Reference Total RNA (SuperArray Bio-
science Corporation) was used as a reference. The result-
ing data files from Agilent Feature Extraction Software
(version 9.5.1.1) were imported into the Agilent Gene-
Spring GX software (version 11.0) for further analysis. A
fold-change cutoff of 2 was used to determine differential
gene expression.
Real time quantitative polymerase chain reaction
(qRT-PCR)
Total RNA from bladder cancer cell lines, extracted as
described above, was reverse transcribed using random
hexamere primers and AMV reverse transcriptase
(Thermo Scientific). Quantitative Real Time PCR was
performed using Maxima SYBR Green/ROX qPCR Mas-
ter Mix (Thermo Scientific) and a BioRad CFX96 ™ Real-
Time PCR Detection System. Each sample was run in
duplicate and expression values were normalized against
TATA-binding protein (TBP). The primer sequences are
shown in Table 2.Results
Identification of the common amplicon at 1p21-22
The CLAC-analysis of the aCGH data from clinical sam-
ples and bladder cancer cell lines showed a region of in-
creased copy number at chromosome 1p21-22 in 5 of 7
total clinical samples as well as in bladder cancer cell lines,
5637, RT4, T24, SW780 and SCaBER (data not shown).
According to aCGH, the common region of gain com-
prised of 2 Mb.
Fine mapping of the 1p21-22 region
The region 1p21-22 was studied in bladder cancer cell
lines by FISH analysis on interphase nuclei (Figure 1).
All cell lines showed increased copy number of 1p21-22
region, and SCaBER cells where the only one which
showed high-level amplification of the region (Figure 1b).
We extensively analyzed cell lines with the PAC/BAC
clones spanning a total of 6 Mb and were able to identify a
minimal region of amplification between the chromosomepositions 92,940,318 and 93,828,148 (Table 2). Ac-
cording to UCSC Genes Feb. 2009 GRCh37/hg19, a
total of 11 human genes are located within the ampli-
con. Nine of them are known protein-coding genes
(Table 3).
Microarray and qRT-PCR validation
The analysis of gene expression by microarray showed
significant overexpression of 4 genes, namely DR1, EVI5,
RPL5 and TMED5 only in the SCaBER, which harbors
the highest level of amplification of the region (Figure 2).
The results were validated by qRT-PCR and confirmed
the overexpression of the genes in SCaBER, as compared
to all the other cell lines (Figure 3). In addition, Onco-
mine database analysis for DR1 expression in bladder
cancer revealed a statistically significant (P < 0.0001) up-
regulation of the gene in clinical samples of both super-
ficial and infiltrating bladder cancer, when compared to
normal bladder [37] (Figure 4). TMED5 showed signifi-
cant upregulation in superficial bladder cancer, when
compared to normal, whereas RPL5 and EVI5 did not
show significant changes of expression levels in the same
dataset.
Discussion
In this study, aCGH technology was utilized to identify
new regions of amplifications in bladder cancer. Recurrent
amplification was found in chromosomal locus 1p21-22.
Subsequently, the locus was fine-mapped and character-
ized in the bladder cancer cell lines. Of the cell lines SCa-
BER showed the highest amplification of the region, thus
it was used for mapping the amplicon. Fine mapping with
the SCaBER model, the region was defined to ~1 Mb of
size, containing 11 genes.
cDNA microarray and qRT-PCR analyses were used to
measure the expression of these genes in bladder cancer
cell lines. DR1, EVI5, RPL5, and TMED5 showed overex-
pression in SCaBER compared to the other cell lines.
DR1 was found to be the most significantly overex-
pressed of the examined genes. Since SCaBER is a squa-
mous cell carcinoma cell line, we wished to interrogate
whether DR1 is overexpressed also in the urothelial
carcinoma. We utilized Oncomine database of clinical
samples, which showed overexpression of DR1 also in
superficial and infiltrating bladder cancer.
DR1 is also known as NC2beta and has been shown to
bind DRAP1 to repress RNA polymerase II gene tran-
scription [38]. Despite targeting the general transcription
Figure 3 qRT-PCR validation of microarray expression data. DR1 (a), EVI5 (b), RPL5 (c) and TMED5 (d), showing the highest level of
expression in the SCaBER model, when compared to the other cell lines tested. The expression values of the genes were normalized against TBP.
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respond to the DR1/DRAP1 inhibition [39] and the op-
posite transcription inducing effect of DR1/DRAP1 has
also been shown for some mRNAs, suggesting the possi-
bility of a specific regulatory effect [40].
According to Oncomine database DR1, EVI5, TMED5
and RPL5 are co-amplified also in brain [41-43], colon
[44], lung cancer [45] and melanoma [46], indicating thatFigure 4 DR1 expression in bladder cancer according to Oncomine. S
found in superficial (a) and infiltrating (b) bladder cancer, when compared
Sanchez-Carbayo study (Sanchez-Carbayo et al., 2006).amplification of 1p21-22 may be a recurrent alteration in
several different types of cancers.
Conclusions
We have identified and mapped a common chromo-
somal amplification at 1p21-22 in bladder cancer. Squa-
mous cell carcinoma cell line SCaBER, which had the
highest level of amplification of the region, showedtatistically significant (p < 0.0001) upregulation of DR1 expression was
to normal bladder. A total of 157 samples were used in the
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http://www.biomedcentral.com/1756-0500/7/547overexpression of DR1. In a published data set, DR1 was
also overexpressed in clinical samples of superficial and
infiltrating bladder cancers, suggesting that DR1 is a pu-
tative target for the amplification. Further studies are
needed to assess the role of the amplification at 1p21-22
in bladder cancer.
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